INmune Bio, Inc. INMB
2.03
0.03
1.50%
as of 25 Sep
- Market cap
- $55.5M
- P/E
- 0.0×
Follow INMB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
4.10 | 3.48 | 4.11 | 3.94 | |
Current Ratio |
4.17 | 3.55 | 4.24 | 4.04 | |
Net Debt/EBITDA |
3.73 | 4.57 | 3.71 | 13.06 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.56 | 0.63 | 2.49 | |
Capex/Depreciation |
(6.89) | (2.55) | 0.00 | (6.52) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.12) | (0.13) | (0.12) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.21) | (0.12) | (0.13) | (0.13) | |
Cash per Share |
1.04 | 1.00 | 0.80 | 0.69 | |
Shareholders Equity per Share |
0.95 | 0.95 | 0.74 | 0.76 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.95 | 0.95 | 0.74 | 0.76 | |
Free Cash Flow |
(5.63) | (3.09) | (3.40) | (3.60) | |
Working Capital |
23.31 | 21.47 | 17.43 | 17.91 | |
Capital Expenditures |
(0.19) | (0.14) | — | (0.43) | |
Net Current Asset Value |
22.69 | 21.06 | 16.63 | 17.32 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Receivables |
1.94 | 2.98 | 1.09 | 3.46 | |
Average Payables |
8.77 | 7.18 | 5.99 | 6.47 | |
Average Assets |
43.07 | 35.96 | 31.81 | 32.26 | |
Average Common Equity |
32.03 | 27.81 | 24.65 | 24.61 |
Columns are period end dates